New combo shows promise for tough esophageal cancer

This study tested a two-step treatment for people with advanced esophageal or stomach cancer that has a specific genetic marker (MGMT deficiency). First, patients took a chemotherapy-like drug (temozolomide) to prime the tumor, then received an immunotherapy drug (nivolumab). The goal was to see if this combination could shrink tumors or stop them from growing. The study included 13 adults whose cancer had already been treated with standard chemotherapy.